ReShape Competitors

Delisted . USA . 
Stock . ReShape Lifesciences
RSLSDelisted Stock  USD 15.68  3.60  29.80%   
ReShape Lifesciences competes with Nuwellis, SINTX Technologies, NanoVibronix, Digital Brands, and Palisade Bio; as well as few others. The company conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. Analyzing ReShape Lifesciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of ReShape Lifesciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of ReShape Lifesciences competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.1515.6831.21
Details
Intrinsic
Valuation
LowRealHigh
0.7014.0029.53
Details
Naive
Forecast
LowNextHigh
1.9617.4833.01
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
7.0110.9614.91
Details

ReShape Lifesciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between ReShape Lifesciences and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of ReShape and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of ReShape Lifesciences does not affect the price movement of the other competitor.

High positive correlations

DBGI
+ 0.81
NUWE
NAOV
+ 0.66
NUWE
DBGI
+ 0.63
NAOV
MTVA
+ 0.61
DBGI
MTVA
+ 0.54
NUWE
ENSC
+ 0.54
DBGI
  

High negative correlations

PALI
- 0.56
SINT
SINT
- 0.35
NUWE
DBGI
- 0.32
SINT
MTVA
- 0.21
PALI
NAOV
- 0.2
SINT
PALI
- 0.16
NAOV

Risk-Adjusted Indicators

There is a big difference between ReShape Stock performing well and ReShape Lifesciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ReShape Lifesciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

ReShape Lifesciences Competitive Analysis

The better you understand ReShape Lifesciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, ReShape Lifesciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across ReShape Lifesciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
RSLS NUWE SINT NAOV DBGI PALI ENSC MTVA
 29.80 
 15.68 
ReShape
 1.32 
 5.22 
Nuwellis
 7.06 
 3.49 
SINTX
 7.36 
 5.40 
NanoVibronix
 0.00 
 10.70 
Digital
 2.74 
 0.75 
Palisade
 0.97 
 2.05 
Ensysce
 1.56 
 0.65 
MetaVia
Market Volatility
(90 Days Market Risk)
Unstable
Extremely Dangerous
Somewhat reliable
Very risky
Relatively risky
Out of control
Slightly risky
Moderately volatile
Market Performance
(90 Days Performance)
Soft
Weakest
Fair
Weakest
Weakest
Weak
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
Risky
High
Strong
Risky
Small
Risky
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Buy
Buy
Not Available
Not Available
Strong Buy
Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Current Ratio
2.12 X
4.55 X
2.11 X
3.07 X
0.13 X
2.59 X
0.87 X
N/A
Net Asset
4.79 M
9.86 M
9.41 M
3.63 M
19.89 M
10.88 M
5.6 M
16.26 M
Profit Margin
(0.48) %
(1.76) %
N/A
N/A
(1.51) %
N/A
(0.89) %
N/A
EBITDA
(6.67 M)
(5.24 M)
(9.61 M)
(3.69 M)
(10.2 M)
(14.86 M)
(6.73 M)
(28.79 M)
Operating Margin
(1.65) %
(1.68) %
(17.33) %
(8.05) %
(0.88) %
N/A
(1.28) %
N/A
Current Valuation
35.03 M
704.91 K
8.72 M
2.39 M
53.89 M
1.95 M
4.3 M
(7.09 M)
Price To Book
30.42 X
2.58 X
2.39 X
0.11 X
6.76 X
2.68 X
1.80 X
1.11 X
Retained Earnings
(642.7 M)
(298.79 M)
(281.74 M)
(69.8 M)
(127.1 M)
(135.94 M)
(129.54 M)
(135.86 M)
Current Asset
N/A
N/A
142.74 M
1.78 M
N/A
N/A
N/A
N/A
Beta
1.9
-0.005
0.65
1.84
0.39
1.41
1.02
-0.22
Number Of Employees
17
38
20
31
41
8
7
9
Shares Outstanding
2.39 M
902.66 K
2.73 M
796.89 K
4.49 M
9.12 M
2.37 M
8.62 M
Cash Flow From Operations
(4.43 M)
(9.59 M)
(8.64 M)
(2.52 M)
(6.15 M)
(12.19 M)
(7.5 T)
(24.71 M)
Total Debt
967 K
545 K
4.03 M
116 K
6.55 M
169 K
301.66 K
136 K
Return On Equity
-1.2
-4.41
-1.95
-0.38
-2.67
-1.88
-2.9
-1.61
Return On Asset
-0.53
-0.79
-0.38
-0.17
-0.24
-0.78
-0.99
-0.74
Number Of Shares Shorted
209.03 K
64.58 K
200.69 K
301.83 K
N/A
335.79 K
135.76 K
43.5 K
Book Value Per Share
(8.66) X
(17.00) X
1.57 X
51.41 X
1.58 X
0.55 X
1.42 X
1.50 X
Current Liabilities
N/A
N/A
82.18 M
297 K
N/A
N/A
N/A
N/A
Total Asset
4.79 M
9.86 M
9.41 M
3.63 M
19.89 M
10.88 M
5.6 M
16.26 M
Debt To Equity
0.01 %
0.07 %
0.34 %
0.01 %
N/A
0.23 %
6.91 %
N/A
Short Ratio
0.48 X
0.03 X
0.97 X
0.28 X
0.01 X
0.34 X
0.18 X
1.11 X
Target Price
1.0
11.0
28.0
10.5
N/A
8.0
20.23
16.0
Shares Owned By Institutions
1.30 %
1.49 %
5.92 %
0.74 %
N/A
5.91 %
6.03 %
10.53 %
Market Capitalization
9.35 M
4.71 M
9.51 M
4.3 M
48.03 M
7.03 M
6.09 M
14.42 M
Price To Earnings To Growth
(12.12) X
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Earning
N/A
N/A
18.35 X
(5.34) X
N/A
0.16 X
N/A
N/A
Price To Sales
1.30 X
0.57 X
5.11 X
1.84 X
5.52 X
14.03 X
0.82 X
N/A
Net Income
(7.13 M)
(11.16 M)
(11.02 M)
(3.71 M)
(13.11 M)
(14.44 M)
(7.99 M)
(27.59 M)
Earnings Per Share
(830.44) X
(313.92) X
(8.40) X
(172.70) X
45.15 X
(3.64) X
(3.51) X
(4.29) X
Shares Owned By Insiders
10.62 %
2.92 %
11.69 %
1.04 %
0.10 %
0.24 %
0.34 %
63.46 %
Revenue
8.01 M
8.74 M
2.89 M
2.56 M
11.56 M
N/A
5.21 M
N/A
Working Capital
(397 K)
6.3 M
2.79 M
609 K
(16.12 M)
7.26 M
3.14 M
7.8 M
Cash And Equivalents
11.49 M
12.05 M
4.78 M
3.94 M
802.72 K
5 M
3.15 M
N/A
Cash Per Share
0.51 X
0.38 X
0.09 X
0.14 X
0.01 X
0.23 X
0.10 X
N/A
Gross Profit
4.57 M
5.19 M
1.16 M
750 K
1.95 M
N/A
(1.89 M)
N/A
Day Typical Price
15.16
5.18
3.49
5.34
10.11
0.74
2.07
0.64
Accumulation Distribution
0.4
0.0602
0.12
0.0986
0.21
0.0533
0.0425
0.0758
Market Facilitation Index
7.4
0.32
0.46
0.55
2.36
0.04
0.09
0.05
Daily Balance Of Power
0.4865
(0.22)
0.5
0.6727
N/A
0.5
(0.22)
0.2
Period Momentum Indicator
3.6
(0.07)
0.23
0.37
N/A
0.02
(0.02)
0.01
Rate Of Daily Change
1.3
0.99
1.07
1.07
1.0
1.03
0.99
1.02
Day Median Price
14.9
5.16
3.49
5.31
9.82
0.73
2.08
0.64
Price Action Indicator
2.58
0.025
0.12
0.28
0.88
0.03
(0.04)
0.02
Relative Strength Index
54.26
28.83
64.65
33.44
48.9
46.08
46.56
49.29
Coefficient Of Variation
2106.55
(1,351)
1293.12
(1,554)
(24,775)
2668.15
(1,955)
33401.52
Mean Deviation
9.35
9.44
2.72
6.46
5.99
4.81
2.87
2.88
Jensen Alpha
0.7887
(1.70)
0.1126
(1.02)
(0.30)
(0.0007)
(0.41)
0.1021
Total Risk Alpha
(1.25)
(4.16)
(0.20)
(2.21)
(1.14)
(0.72)
(0.66)
(0.61)
Sortino Ratio
0.0516
N/A
0.0469
N/A
N/A
0.0328
N/A
(0.02)
Downside Variance
150.6
N/A
15.29
N/A
N/A
34.71
N/A
19.15
Standard Deviation
15.53
20.61
3.72
11.46
8.55
7.94
3.62
4.79
Kurtosis
5.57
27.48
1.2
9.12
1.84
12.21
0.9103
16.12
Potential Upside
35.81
13.52
6.57
8.36
14.51
8.0
4.81
4.35
Treynor Ratio
(1.11)
(0.88)
0.1585
(0.26)
(0.02)
0.0939
(0.09)
(0)
Maximum Drawdown
94.41
158.52
17.39
68.19
47.28
53.96
20.63
35.49
Variance
241.03
424.61
13.81
131.37
73.16
62.98
13.11
22.93
Market Risk Adjusted Performance
(1.10)
(0.87)
0.1685
(0.25)
(0.01)
0.1039
(0.08)
0.0058
Risk Adjusted Performance
0.0446
(0.04)
0.0651
(0.04)
0.0062
0.0367
(0.03)
0.0107
Skewness
1.51
4.36
(0.01)
2.34
0.2828
2.67
(0.66)
2.85
Semi Deviation
10.64
N/A
3.38
N/A
N/A
5.07
N/A
3.39
Information Ratio
0.0408
(0.08)
0.0493
(0.07)
(0.02)
0.0244
(0.08)
(0.02)
Value At Risk
(18.97)
(21.18)
(5.76)
(12.80)
(12.08)
(10.23)
(5.45)
(6.85)
Expected Short fall
(12.28)
N/A
(3.18)
N/A
N/A
(6.64)
N/A
(3.82)
Downside Deviation
12.27
N/A
3.91
N/A
N/A
5.89
N/A
4.38
Semi Variance
113.24
N/A
11.39
N/A
N/A
25.73
N/A
11.48

ReShape Lifesciences Competition Performance Charts

Five steps to successful analysis of ReShape Lifesciences Competition

ReShape Lifesciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by ReShape Lifesciences in relation to its competition. ReShape Lifesciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of ReShape Lifesciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact ReShape Lifesciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to ReShape Lifesciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your ReShape Lifesciences position

In addition to having ReShape Lifesciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Drugs Thematic Idea Now

Drugs
Drugs Theme
Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. The Drugs theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Drugs Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Other Consideration for investing in ReShape Stock

If you are still planning to invest in ReShape Lifesciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ReShape Lifesciences' history and understand the potential risks before investing.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY